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NOS-BASED BIOPOLYMERS; TOWARDS NOVEL
THROMBORESISTANT NO-RELEASE MATERIALS

CHARBEL ABOU DIWAN
ABSTRACT
Nitric Oxide releasing biopolymers have the potential to
prolong vascular graft and stent potency without adverse systemic
vasodilation. It was reported in literature that eNOS-overexpressing
endothelial cell seeding of synthetic small diameter vascular grafts
decreased human platelet aggregation by 46% and bovine aortic smooth
muscle cell proliferation by 67.2% in vitro. We hypothesized that
incorporating the enzyme nitric oxide synthase (NOS) in biocompatible
polymeric matrix will provide a source of NO that utilizes endogenous
compounds to maintain an unlimited supply of NO. To test this
hypothesis, we have incorporated the enzyme nitric oxide synthase into a
polyethyleneimine film using a layer-by-layer electrostatic deposition.
This approach will provide a source of NO that utilizes endogenous
compounds available in the blood matrix to maintain a constant supply of
NO at the blood/device interface. When coated onto the surface of
various blood-contacting implantable medical devices, it will provide NO
iv

fluxes at levels equal or greater than the normal endothelial cells, and for
extended time periods. This configuration will help solve the issues of
both thrombosis and stenosis that occur as side effects for several types
of biomedical implants.
Our results indicate a proof of principle of a new approach for
making antithrombotic coatings for medical devices and implants based
on NO release. We have demonstrated that NOS-based polymetric films
successfully generate NO under physiologic conditions at small levels
equal to and higher than those observed for endothelial cells. The level of
NO release can be fine-tuned through varying the number of NOS layers
in the film buildup. We have shown that NO fluxes from our NOS-based
PEI films are sustained for prolonged periods of time, which has the
potential of producing efficient, short and long-term, antithrombotic
coatings for medical devices and blood-contacting tools such as stents
and catheters. We also show that NO release from these coatings
successfully decrease platelet adhesion at the surface by 60%. This, and
other properties are key for the desired thromboresistivity needed for
blood-contacting medical devices.
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CHAPTER I
INTRODUCTION

1.1

BIOCOMPATIBILITY

ISSUES

OF

IMPLANTABLE

MEDICAL DEVICES

The thrombogenic nature of various polymeric materials utilized to
prepare various blood-contacting and implantable medical devices such
as vascular grafts, intravascular catheters and sensors, coronary artery
and vascular stents, even if labeled as biocompatible, can cause serious
complications in patients [2]. Upon introduction of a foreign material into
the blood stream, key proteins of the coagulation cascade (fibrinogen,
and von Willebrand’s factor) adsorb to the surface, followed by platelet
adhesion and activation, leading to fibrin and thrombus formation at the
surface (Figure 1.1) [3].
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Figure 1.1: Illustration showing thrombus formation at the surface of
implantable medical devices. Upon exposure to blood, protein adsorption
occurs, followed by platelet adhesion at the surface. Platelet activation
leads to thrombus formation at the surface.

2

An anti-coagulation regiment, with the adverse effects associated
with long term use, is typically required to clinically reduce the risk of
thrombus formation [4]. Thrombus formation and generation involves
two synergistic events; a cGMP-dependant mechanism that involves
platelet activation, adhesion and aggregation [5], and fibrin formation
resulting from the binding of bivalent fibrinogen to glycoprotein IIb/IIIa
[6].
In addition to thrombus formation, certain medical devices, during
the implantation process can damage the endothelium lining of blood
vessels, leading to smooth muscle cell proliferation, and ultimately cause
vascular stenosis via neointimal hyperplasia [7,8]. Further more, bacterial
adhesion at the material surface of medical devices leads to deviceassociated infections [9]. Early bacterial adhesion is mediated by
reversible bacteria-substrate interactions, followed by irreversible
molecular bridging at longer times [10]. Upon adhesion, certain bacteria
are capable of secreting an exopolysaccharide matrix forming a
protective biofilm that retains nutrients and protects the bacteria from the
host immune response. Biofilms provides bacterial resistance to
traditional antibiotic therapies [11] .
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Implantation into subcutaneous tissues subjects implants to an
inflammatory response involving the release of fluid and plasma proteins
followed by the recruitment of leukocytes at the implant site. Neutrophils
and monocytes migration and adhesion to the implant surface initiates
phagocytosis. After the initial inflammatory response, a more chronic
response involves a sustained inflammation at the implant site involving
the recruitment of macrophages, monocytes, and lymphocytes.
Eventually, a fibrous capsule composed mainly of macrophages and
collagen is formed around the implanted device.

1.2 THE PROTECTIVE ROLE OF ENDOGENOUS NITRIC
OXIDE (NO)

Endogenous NO production at low concentrations (nanomolar)
plays a critical role in the regulation of vascular hemostasis [12].
Endothelium derived NO production inhibits platelet adhesion [13],
aggregation [14], and their further recruitment to the growing thrombus
[15]. NOS inhibition is associated with the shortening of bleeding times
in healthy volunteers [16], and platelet accumulation in the vasculature of
animals [17]. In vivo studies involving production of high levels of NO

4

from iNOS showed the ability to prevent platelet adhesion [18]. NO,
prostacyclin, and ecto-AD(T)Pase are potent inhibitors of platelet
function that are produced by an intact endothelium [19]. Nitric oxide
diffuses into platelets stimulating cGMP production by soluble guanylyl
cyclase causing a decrease in cytosolic Ca2+ levels by directly inhibiting
voltage-gated Ca2+ channels [20]. Calcium acts as an important second
messenger with an intracellular concentration 50-100nM in resting
platelets. Upon platelet activation, intracellular calcium concentrations
can rise up to 1mM [21], triggering a cascade of events that leads to
platelet aggregation.
The regulatory effect of NO on cGMP and cGMP-dependant
protein kinases was reported by a significant increase in platelet
aggregation in the presence of guanylyl cyclase inhibitors [22,23], and by
the potentiation of anti-platelet effects in the presence of cGMP
phosphodiesterase inhibitors [24]. Reduction in Ca2+ levels via a cGMP
dependant mechanism inhibits thrombin mediated activation of
phosphoinositide 3-kinase (PI-3 kinase) [25,26] leading to a suppression
of the conformational change of glycoprotein IIb/IIIa required for
fibrinogen binding [27], which decreases the number and affinity of
fibrinogen binding sites on the platelet surface [28]. cGMP is also

5

involved in increasing intracellular cAMP indirectly by inhibiting the
phosphodiesterase III (PDE III) dependant degradation of cAMP [29].
Increased levels of cAMP has been associated with decreased levels of
intracellular Ca2+ flux [30,31]. In addition cGMP down-regulates protein
kinase C leading to regulation of the surface expression of α granule
protein P-selectin, a mediator of platelet adhesion [32].
There have been various reports indicating NO release from resting
[33] and aggregating platelets [24,34]. NO levels from activated human
platelets have been indirectly measured and is estimated at 11.2
pmol.min-1/108 cells [33]. NO temporarily inactivates platelets in the
close proximity of the endothelium [35-37]. This inhibition is short-lived
and NO is rapidly scavenged by oxygen and hemoglobin in plasma
[38,39].
NO is produced by macrophages as part of the natural immune
response to bacterial infections [40,41]. NO is shown to mediate the
inhibition of a wide variety of Gram-negative and Gram-positive
bacterial species [42], as well as reducing bacterial adhesion [43].

6

1.3

THE ROLE OF NO-RELEASING MATERIALS AS
COATINGS FOR IMPLANTABLE MEDICAL DEVICES

Considerable research is being focused on improving the
surface chemistry of materials used as outer coatings of implantable
medical devices [3]. NO releasing polymers have the potential to be
effective in preventing platelet adhesion, activation, and aggregation onto
the surfaces, therefore reducing the risk of thrombus formation at these
surfaces. They have the potential to prolong vascular graft and stent
potency without adverse systemic vasodilation [44]. NO exhibits a short
half-life <1s in the presence of oxygen and hemoglobin, there is no
systemic effects that can be caused by the NO-releasing coatings because
any NO released will be rapidly consumed locally near the surface of the
device [45]. Numerous approaches are currently being investigated in an
attempt to develop polymeric materials that are more blood-compatible.
In general, these approaches can be categorized into two main trends:
first, methods that mimic endothelial cells anti-thrombogenic properties
[46-50], and, second, methods that use modified chemical surfaces and
added moieties that exhibit decreased protein and cell adhesion [1].
Prevention of protein adhesion in vivo is generally difficult to achieve,
therefore the other approach, which aims at the development of NO-

7

releasing surfaces akin to native endothelial cells, appears more
promising. Nitric oxide, thrombomodulin, prostacyclin, and heparans
contribute to the non-thrombogenic properties of the endothelial cells
[2,51]. Polymers that possess chemical platforms with the ability of
releasing NO have been shown to be more thromboresistant. A potential
solution can be found in polymeric materials that are capable of releasing
low levels of nitric oxide at the blood/polymer interface.

1.4 CLASSES OF NO-RELEASING MATERIALS

Two classes of NO-releasing materials have been explored
(Figure 1.2). N-diazeniumdiolate based NO-releasing polymers [52-56],
and Nitrosothiol-based NO-releasing polymers [57-61] .
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Figure 1.2: Generic structure of (A) Diazeniumdiolates (I)
zwitterionic, (II) cation stabilized. (B) S-Nitrosothiol. Adapted
from [1]

9

1.4.1 N-Diazeniumdiolates

N-diazeniumdiolates are inorganic NO donors formed by the
reaction of a secondary amine structure with 2 moles of NO gas under
high pressure, creating a relatively stable adduct structure [62-64]. A
countercation is required to fulfill electroneutrality of the negatively
charged diazeniumdiolate adduct, leading to zwitterionic molecules [1].
Three general structural types of diazeniumdiolates have been outlined
for preparing diazeniumdiolates based NO-releasing polymers: Dispersed
non-covalently bound small molecules where the diazeniumdiolate group
is attached to amines in low molecular weight compounds; covalently
bound diazeniumdiolates group to polymeric side chains or to the
polymeric backbone [56].
Since this initial work, additional methods for preparing NOreleasing polymers utilizing diazeniumdiolates as NO donors were
described by both Pulfer et al. [55] and Zhang et al. [54] Pulfer and coworkers developed NO releasing PEI microspheres that were entrapped
into vascular grafts pores [55]. Zhang and co workers prepared
diazeniumdiolate nanoparticles by reacting NO with alkylamines tethered
onto the surface of fumed silica particles (7-10nm diameter) [54].
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Diazeniumdiolated-dimethylhexyldiamine (DMHD/N2O2) were used to
prepare NO-releasing polymers as coatings for oxygen sensors [65], and
extracorporeal circuits [46]. In other studies, diethylenetriamine
diazeniumdiolate (DETA/ N2O2) was embedded into ethylene-vinyl
acetate [66,67]. In other work, diazeniumdiolate-spermine (SPER/N2O2)
was incorporated into a biodegradable polymer used to construct jugular
vascular grafts [68]. Although initial studies proved the worthiness of
such materials, leaching of the water-soluble diazeniumdiolates was
shown to form nirtosoamine, a well known class of carcinogens, due to
the oxidation of local NO to an NO+ intermediates that form RN-NO
species upon reactions with amine compounds [69]. To counter this
problem, more lipophilic discrete dialkyldiamine diazeniumdiolates such
as dibutylhexyldiamine diazneniumdiolate (DHBD/N2O2) were prepared
that have higher octanol/water partition coefficients and would be more
likely to stay in polymer phase, even if nitrosoamine formation occurs
[44]. The use of a diazeniumdiolate substrate that would be benign upon
leaching was used as another method to avoid the buildup of
carcinogenic species. The amino acid L-proline was used to prepare the
anionic diazeniumdiolate of proline (PROLI/N2O2), and thus the
nitrosamime form of proline is non- carcinogenic and would therefore be

11

harmless

to

the

patient

[70].

The

covalent

attachement

of

diazeniumdiolate moiety to the polymer backbone was used to prevent
leaching of any potentially carcinogenic species. Diazeniumdiolated
silicone rubbers were prepared by the use of diamino- and triaminoalkyltrimethoxysilanes

cross-linkers

with

hydroxyl

terminated

polydimethylsiloxanes followed by reaction with NO [48]. Anionic
diazeniumdiolated polymethacrylates were prepared by copolymerizing
various secondary amine-containing monomers with methyl-methacrylate
[71]. A protected diazeniumdiolated poly(vinyl chloride) was synthesized
by using the O(2)-alkylated diazeniumdiolate of piperazine as a linker for
incorporation of the diazeniumdiolate onto the polymeric backbone [72].
Alternative matrices for the incorporation and covalent attachement of
diazeniumdiolates have been investigated and include sol-gels and
hydrogel

dressings.

Discrete

diazeniumdiolates

(DETA/N2O2),

dipropylenetriamine diazeniumdiolates (DPTA/N2O2), and DPTA/N2O2g-dextran, were suspended in a hydrogel matrix [73]. The synthesis of sol
gel materials by reaction of alkoxylsilanes with alkyltrimethoxysilanes
followed by exposure to NO has been reported [74]. In addition,
hydrogels as NO carriers were prepared by reacting polyethylene glycol
N-hydroxysucinimide monoacrylate with poly L-lysine and then
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dissolving the product in water followed by the exposure to NO [57], and
by the reaction of NO with cross-linked poly(vinyl-acetate) modified
with amine groups [75].

1.4.2 S-Nitrosothiols

The second class of NO donors are S-nitrosothiols; they are
thought to serve as NO reservoirs and transporters within biological
systems [76]. S-Nitroso-albumin and S-nitrosoglutathione are the most
abundant naturally occurring S-nitrosothiols circulating in blood [77].
The cleavage of the S-NO bond releases NO by three known mechanisms
[78]: copper mediated decomposition[79], the direct reaction of ascorbate
[80], and photolytic decomposition [81]. S-nitrosothiols have been
covalently linked to the polymer to prevent leaching of the donor or
reaction byproducts. NO releasing hydrogels were prepared by linking
cysteine to Polyethylene glycol (PEG) and reacting the resultant
copolymers with sodium nitrite to form S-nitrosocysteine groups [57].
The S-nitrosothiol (GSNO) and S-nitroso-N-acetylcysteine (SNAC) were
blended into poly(ethylene oxide) and poly(propylene oxide) copolymers
or PEG for targeted deliver of NO in biomedical applications [58,59]. In
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addition, S-nitrosothiols can be tethered to the surface of polymer fillers.
S-nitroso-N-acetylpenicillamine (SNAP) was tethered to the surface of 710nm diameter fumed silica particles [82].
The greatest limitation of these approaches is that they are a finite
reservoir of NO, which will limit their potential use in more permanent
types of implants, and the NO fluxes achieved so far are lower than NO
released from endothelial cells [1]. Studies have shown that stimulated
human endothelial cells continuously generate NO at a level of ca. 4x1010

mol.cm-2.min-1 [83].

1.5 NOS BASED NO-RELEASING MATERIALS

The logical alternative is then to explore approaches that would lead
to materials with the ability to sustain NO generation for longer
durations. Some current developments include materials that utilize
endogenous NO donors such as S-nitrosothiols and nitrite to generate NO
[84-86]. Though these approaches display potential, with their current
limitations, it is not likely to overcome the complexity of the
biocompatibility issues of medical devices.
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Developing a NO-releasing surface that closely resembles the
endothelium is the key to achieving better thromboresistivity. The
endothelial isoform of the enzyme Nitric Oxide Synthase, eNOS, is a key
component of the endothelial cell lining. It was reported that eNOSoverexpressing endothelial cells seeding of synthetic small diameter
vascular grafts decreases human platelet aggregation by 46% and bovine
aortic smooth muscle cell proliferation by 67.2% in vitro [87]. NO
releasing materials using Polyethyleneimine (PEI), a biocompatible
polymer [88], has been reported in literature [55,89,90]. In our lab, NO
was successfully generated from the enzyme Nitric Oxide Synthase
embedded in bilayered cast film of didodecyldimethylammonium
bromide surfactant [91]. We have incorporated the oxygenase domain of
the enzyme Nitric Oxide Synthase (NOSoxy) in a Polyethyleneimine
polymeric matrix by means of layer-by-layer electrostatic adsorption
[92,93] to construct a multi-component protein film that mimics the NOgenerating behavior of the endothelial cell lining. We have demonstrated
that our films provide a source of NO that utilizes endogenous
compounds to maintain a continuous supply of NO at levels that are in
the same range as that of endothelial cells [94].

15
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CHAPTER II

LAYER-BY-LAYER ASSEMBLY OF PROTEIN FILMS

2.1 INTRODUCTION

The technique of ultrathin film assembly via alternate adsorption
of oppositely charged polyions was developed a couple of decades ago.
In 1991, the alternate adsorption of linear polycations and polyanions as a
method for film assembly was first introduced by Decher and co-workers
[1-9]. The basis of this method is the excessive adsorption at every stage
of the polycation/polyanion assembly that leads to recharging of the
outermost surface at during the film formation.
This methodology relies on the following principle: a negatively charged
substrate surface is immersed in a cationic polyelectrolyte solution
allowing the electrostatic adsorption of the polycationic layer. Since high
32

concentrations of polyelectrolytes are utilized, a number of cationic
groups remain exposed and thus the surface charge is effectively
reversed. After rinsing with water, the substrate is immersed in an
anionic polyelectrolyte solution restoring the original surface charge. By
repeating both steps, alternating multilayer assemblies are obtained with
repeatable layer thickness (scheme 2.1) [10].
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Figure 2.1: Scheme of layer-by-layer film assembly on a solid substrate
by alternate adsorption of linear polycations and polyanions/negatively
charged proteins.
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Electrostatic layer-by-layer self-assembly has been applied to thin
film coatings [6,11-13]. It allows the assembly of multilayers of materials
on two-dimensional (2D) supports and on three-dimensional (3D)
nanotemplates [14]. A variety of charged materials have been used in
these 2D and 3D nanoassembly processes; they include linear
polyectrolytes (synthetic and natural), enzymes, antibodies, viruses, and
inorganic nanoparticles [14]. The resulting film architecture can be
designed to meet different requirements such as biocompatibility,
stability, and thickness, typically on the order of tens to hundreds of
nanometers [14,15]. Layer-by-layer organized film assembly based on
the alternate adsorption of oppositely charged macromolecules paves the
way for a molecular architecture in the direction perpendicular to the
solid support allowing for the design of films with nanometer resolution.
Ultrathin films can be designed with definite molecular composition and
ordered architecture in the range of 5-1000 nm with a precision better
than 1nm [16]. Layer-by-layer assembly allows the control of the
chemical composition of the films, which translates into control of the
biological activity in biomedical applications. Ultrathin film coatings of a
surface can maintain its original mechanical properties and structure [17].
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For enzyme-based thin films, electrostatic adsorption seems to be
one of the simplest ways for enzyme immobilization [15]. Other
available methods of enzyme immobilization include physical adsorption
[18], encapsulation [19], or covalent attachment [20,21]. However, these
methods have disadvantages in terms of stability and low active site
accessibility/activity. Site-targeted immobilization is complex but can
provide enhanced activity if the immobilization does not interfere with
enzyme function [22-24].

2.2 GENERALITY OF THE ASSEMBLY PROCEDURE

Layer-by-layer assembly of multilayered protein films has been
performed by means of alternate electrostatic adsorption of either
positively charged polyethyleneimine (PEI), poly(allylamine) (PAA),
poly(dimethyldiallylammonium)

(PDDA),

or

negatively

charged

poly(styrenesulfonate) (PSS), DNA, and heparin [8,10,25-38]. The pH of
the protein component was set far from the isoelectric point in order to
ensure

sufficient

charge

under

experimental

conditions.

The

concentration range of aqueous proteins was 0.1 – 2 mg/ml or ~ 10-5M.
Examples of aqueous proteins used (table 2.1) were cytochrome c,
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lysozyme, histone type YIII-S, myoglobin (Mb), pepsin, horseradish
peroxidase (POD), hemoglobin, glycoamylase (GAM), concanavalin A
(Con A), albumin [31], Glucose Oxidase [21,10,32], catalase, invertase,
diaphorase [8,10], bacteriorhodopsin [37], and immunoglobulin (IgG)
[33,39]. Protein stability can be affected by the surface structure of the
solid support; therefore precursor films of alternate PEI/PSS were used as
standard surfaces [8,10,29,40]. Solid surfaces are typically immersed in
aqueous protein solutions or polyions for 20 minutes. Surfaces were then
rinsed with water, and dried. To reach saturation of the adsorption
process, the assembly process was carried out uninterrupted. A summary
of the alternate adsorption of 18 water-soluble proteins in combination
with oppositely charged polyions is listed in Table 2.1.
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95000

100000
104000
141000
150000
186000

240000
270000
600000

Glycoamylase

Photosynt. RC
Concanavalin
Alcohol dehydrogenase
IgG[33]
Glucose Oxidase[32]

Catalase
Invertase
Diaphorase

5.5
3.8
5

5.5
5
5.4
6.8
4.1

4.2

4.9

Isoelectric
point
10.1
11
11
7.0
6
1
8.0
6.8

8
7
8.5
7.5
6.8
9.2
6.5
6.5
9.2
7.0
8

-

pH Charge
4.5
+
4
+
7
+
4.5
+
9.4
6
4.2
+
4.5
+
9.2
8
3.9
+
6.8
-

Alternate
with
PSSPSSPSSDNA, PSSPDDA+
PDDA+
PSSPSSPEI+
PDDA+
HeparinPDDA,
PEI+
PDDA+
PEI+
PDDA+
PSSPDDA+
PEI+
PEI+
PAH+
PEI+
PDDA+
PEI+

38

Table 2.1: Protein-Polyion Alternate Multilayer Assembly

68000

Albumin[31]

Molecular
Protein
Weight
Cytochrome c
12400
Lyzozyme
14000
Histone f3
15300
Myoglobin
17800
Bacteriorhodopsin[36]
26000
Pepsin
35000
Peroxidase
42000
Hemoglobin
64000

15
20
20
60
15
15
15
15
20
20
20

13
8.6
12.2
15
12
16.6
51
12.6
9.6
10.8
31

9.0 + 1.0
5.7 + 0.8
8.5 + 1.0
10.0
bilayer 8.0
11.7 + 0.8
34.4 + 0.8
bilayer 8.4
6.4 + 0.8
monolayer 7.3
bilayer 21.0

diameter 9.0
diameter 8.6
diameter 11.5

13 x 7.0 x 4.0
3.9 x 4.0 x 4.2
9.0 x 4.0 x 4.0
14 x 10 x 5
diameter 8

Protein
Thickness
of
Saturation monolayer mass protein polyion Protein globule
time (min) coverage (mg/m2) bilayer [28]
dimensions[28]
12
3.6
2.4 + 1.6
2.5 x 2.5 x 3.7
16
3.5
2.3 + 1.9
3.0 x 3.0 x 4.5
15
3.3
2.2 + 2.0
diameter 3.4
12
6
4.0 + 2.0
2.5 x 3.5 x 4.5
5
7.5
5.0 + 1.0
ca 5.0
20
4.5
3.0 + 0.6
diameter 3.0
15
5.3
bilayer 3.5
diameter 3.5
16
26
17.5 + 3.0
5.0 x 5.5 x 6.5
27
bilayer 18.2
10
23
16.0 + 1.0
11.6 x 2.7 x 2.7
20
30
20.0 + 1.0
15
4
2.6 + 0.5
diameter 6.3

Unlimited cycling of proteins with oppositely charged polyions
is reported. The mass changes were determined as a function of
frequency shifts with Quartz Crystal Microbalance (QCM) measurments
and was quite reproducible. An alternation with a polyion is required due
to the unsuccessful attempts to grow protein films by the cyclic
immersion of a substrate into a protein solution.
QCM, x-ray reflectivity, scanning electron microscopy, and
surface plasmon resonance were the tools used to estimate protein layer
thicknesses. These estimates correspond to known molecular dimensions
of proteins obtained from crystallographic data and suggest the formation
of relatively uniform monolayers. Parameters such as orientation,
packing density, and hydration of proteins within the layer, might have
significant influence on the thickness of the protein monolayer.
The multilayer formation as indicated in Figure 2.1 is quite
general. The physical separation of the individual layers in the films is
assumed on the basis of the regular, stepwise mass increase during the
assembly. However, the layer separation between the proteins and the
oppositely charged polyions may not be as definite, and the linear
polyions would cover the protein surface and act as bridging molecules,
to enhance protein stability.
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Altering the pH around the isoelectric point allows the protein to
be assembled with polyanions and polycations. The protein can be used
at a pH above the isoelectric point (i.e. negatively charged) to assemble
with polycations and at a pH below the isoelectric point (i.e. positively
charged).

Examples

of

both

cases

are

hemoglogbin/PEI+,

hemoglobin/PSS-, and albumin/PDDA, or heparin- multilayers (table 2.1).
The layer-by-layer immobilization of proteins onto solid substrates with
strong polyions (such as PSS, PEI, PDDA) renders it insoluble in a buffer
for a pH range between 3 and 10. Immobilization of proteins with weak
polyions renders it partially soluble in buffers with pH close to the
isoelectric point of one of the components.
Lvov and co-workers demonstrate the dependence of QCM
frequency

shift

on

cycles

of

alternate

Myoglobin

(Mb)

/Polystyrenesulfonate (PSS) adsorption. QCM shifts were proportional to
the adsorbed mass at the surface of quartz crystals, and correspond to
protein monolayer formation at every step of the film formation process
[8,10]. Figure 2.2 represent the typical UV/vis spectra for a Mb/PSS film
at consecutive steps of the assembly, with a linear increase in the Soret
band absorbance (407nm) with the number of myoglobin layers in the
film.
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Figure 2.2: UV/vis spectra of Mb/PSS assembly. The lowest spectrum
corresponds to a precursor film. The following spectra correspond to the
stages after adsorption of 2,4,6,8,10, and 12 alternate MB/PSS layers.
Adapted from [10]
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The assembly of glucose oxidase films (GOD/PEI) was
reported by Lvov and co-workers [10]. The adsorption kinetics of this
process yielded GOD adsorption saturation in 15 minutes. Linear film
mass increases were observed up to at least 21 molecular layers. The
layer thickness for GOD was 34.4nm and 0.8nm for PEI. In addition,
with increasing numbers of GOD layers, a linear increase of the UV/Vis
absorbance was observed [10].
The alternate assembly of glucose oxidase with PDDA was also
reported [10,32]. Layer thicknesses observed with each adsorption cycle
of GOD (8nm with PDDA; 11.7nm with PEI at pH 7; 8.4nm with PAA)
correspond to the diameter of the GOD molecule, suggesting a
monolayer formation [10,32].
Atomic Force Microscopy (AFM) has been used to study
surface morphology of multilayered films at every step of the adsorption
process [41]. Surface roughness corresponded to the sequence of
protein/polyion adsorption. With the protein layer, the surface roughness
was larger and corresponded to the diameter of the globular protein used.
The surface roughness decreased upon the deposition of the polyion
layer.
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2.3 BIOLOGICAL ACTIVITY AND ENHANCED STABILITY OF
PROTEINS IN FILMS

Proteins

assembled

with

polyions

by

the

layer-by-layer

methodology tend to not denature [10,26,27,30,32,33,38]. The retention
of enzymatic activities within the multilayered films was seen with
glucose isomerase, glucoamylase, glucose oxidase, and peroxidase.
Specific reactions was seen between immunoglobulins (IgG) and
antibodies in the multilayered films [33]. The Soret band absorbance of
myoglobin and hemoglobin was used to confirm their native
conformations within the films [8,10,35]. Redox potentials of myoglobin
and cytochrome P450 within those multilayered films corresponded to
the redox potentials of these proteins immobilized onto electrode surfaces
by other methods [35, 37].
Layer-by-layer immobilization of proteins with linear polyions enhanced
their enzymatic stability, and preserved them from microbial attacks.
GOD/PEI multilayered films retained 90% of enzymatic activity after
incubation at 5°C for 3 months. In addition, GOD/PEI multilayered films
show enhanced temperature stability and were active up to 67°C in
comparison to 50°C for GOD in solution. Glucose oxidase retains its
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activity within the multi-layered films up to pH 10 while it drops to a
minimum at pH 9 in solution [32].
The enzymatic activity within the multilayered films increases linearly
with the number of enzyme layers as seen with the GOD/PEI films up to
10 protein layers; when the activity of the film reaches saturation [32].
Saturation in bioactivity is probably due to diffusion limitations of the
substrate in penetrating the film. The extent of accessibility of the
substrate to the proteins within the film depends greatly on the nature of
the film component, due to the transport of the substrate through the
multilayer, and thus puts restrictions on the number of enzyme layers
within the multilayered films.

2.4 PROBLEMS OF THE ASSEMBLY

2.4.1 NONLINEAR GROWTH

Nonlinear film growth with adsorption cycles was seen in some cases,
and it was possible to overcome it in order to reach protein monolayer
formation at every adsorption step by the following methods:
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1. Decreasing of protein concentrations, such as in the case of
pepsin/PDDA, or alcohol dehydrogenase/PDDA films, from
1mg/ml to 0.1mg/ml or less. IgG was also used for assemble at low
concentrations (0.1mg/ml) [33].
2. Altering the pH of the protein solution in order to modulate the
surface charge, as in the case of the GOD/PEI assembly from pH
6.5 to 9.2 [32].
3. Altering the types of polyions used in the layer-by-layer assembly
procedure. In the case of GOD, monolayer formation was achieved
via the change from branched PEI to linear PDDA [10], or PAA
[32].

2.4.2 CHARGED GROUPS ON A PROTEIN GLOBULE SURFACE

Density and location of the charge
The density and location of the charge on the protein surface
can be critical to the assembly process. The electrostatic attraction of
proteins with linear polyions is straightforward, however, the situation is
different with large ions with specific three-dimensional shapes and

45

charge distribution. As an example, the direct assembly of oppositely
charged protein molecules was difficult due to the fact that electrostatic
attractions cannot be maximized with globular proteins. Polyion
anchoring appears to be favored by the “patched” nature of the surface
charge of proteins [42]. Flexible linear polyions can produce optimized
electrostatic attractions and hence may penetrate in between protein
molecules acting as an electrostatic “glue”.

The pH dependance
The number of excess charges on protein surfaces is directly
dependant on the pH. Typically, the number of elemental charges seen
with proteins used in the assembly process ranges from 10 to 60. For
example, an albumin globule gave an elemental charge of +35 at pH 4
[31].

Dependence on the thickness of the underlying polyion layer
The amount of adsorbed proteins was found to depend on the
thickness of the underlying linear polyion layer. Proteins deposited in
alternation with polyions prepared from high ionic strength solutions
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(thickness of polyion layer: 3-4nm) were thicker than the protein layers
deposited in alternation with polyions prepared from water (thickness of
polyion layer 1nm). In multilayers composed of myoglobin/PSS in 0.2M
NaCl, the thickness of the myoglobin layer was of the order of 7nm,
which is double the thickness of the 4nm myoglobin monolayer deposited
in alternation with PSS from water [35]. The amount of immunoglobulins
was found to be double in IgG/PSS in 0.1M NaCl multilayers when
compared to a multilayer with PSS from water [33]. The thicker polyion
layer provides a matrix with a greater area available for protein
deposition, and hence requires more protein to achieve the charge
compensation and reversal. Therefore, the variation in the ionic strength
of the polyion solution may be used as a fine-tune properties of the
protein surface in film buildup.

2.4.3 RELIEF OF SOLID SUPPORT

The stability of the multilayer assembly can be affected by the
surface structure of the solid support. The assembly of hemoglobin,
glucose oxidase, concanavalin, albumin, and myoglobin gave more stable
films than those of cytochrome c and lysozyme. Multilayer assemblies
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onto QCM resonator was successful on all those proteins, while some
difficulties occurred with the assembly onto quartz slides such as in the
case of the alternate assembly of lysozyme onto PSS. Protein multilayers
exhibit high stability when deposited onto silver or gold electrode
surfaces, which have roughness in the tens of nanometers range.

2.4.4 OTHER PROBLEMS
1)

pH in the bulk of the solution might differ from the pH at the
charged polyion surface which could influence the conformation and
activity of proteins in addition to the interaction with the polyion layer
itself.

2)

The relative roughness of the polyion surface. Polymeric tails might
protrude into the bulk solution causing protein aggregation during
adsorption.

3)

Drying of the polyion films might influence the structure.

2.5 CONCLUSIONS
This chapter gives an overall view of fundamental approaches
developed to design organized protein films with precise location of
different protein monolayers. The multilayer film formation utilizing the
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layer-by-layer methodology may be applied to any water-soluble protein
by choosing a solution pH apart from the protein isoelectric point to
provide a surface charge. The films can be used in the following
application areas:

1)

Sensor layers. Multilayered films compromising enzymes layers
provide a quick response to changes in its vicinity when combined
with field-sensitive microelectronic elements. The efficiency of such
sensor layers might be increased by the sequential deposition of the
enzymatic layers that leads to enhanced electron transfer. Conductive
polyions can be used to enhance electrical signaling processing as
well. Protein/polyions multilayered films are insoluble in water and
organic solvents and hence are perfectly suited for such uses.

2)

Biocompatible coatings. Multilayered protein films may be used to
coat surfaces of implants and surgical instruments. The use of
functional proteins allows the preparation of biomimetic surfaces. In
addition, polymer and polyion organic chemistry is extensive and
hundreds of polyions may be used in the assembly with proteins.
Mmultilayered films that result are molecularly thin and have
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desirable architecture and composition. The multilayered protein films
may cover any type of surfaces that carries a sufficient surface charge.
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complexation.

CHAPTER III

NITRIC OXIDE SYNTHASE OXYGENASE BASED NITRIC
OXIDE RELEASE POLYETHYLENEIMINE THIN FILMS

3.1 INTRODUCTION

Graft thrombosis is the cause of 80% of vascular access
dysfunction, a problem with an associated health-care cost of over $1
billion/year [1]. The number of revascularization procedures have
increased dramatically, and is estimated at 15% after initial coronary
revascularization, and approximately 50% after lower extremity bypass
[2, 3]. Stent restenosis occurs at 30% of implant sites as a result of initial
vascular thrombosis followed by cell proliferation, requiring a repeat
angioplasty procedure within 1 year [4].
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The thrombogenic nature of various polymeric materials utilized to
prepare blood-contacting and implantable medical devices such as
vascular grafts, intravascular catheters, sensors, coronary artery and
vascular stents, and a host of other medical tools, even if labeled as
biocompatible, can cause serious complications in patients. Thrombus
formation at the surface of implantable medical devices is the major
cause of vascular access dysfunction requiring secondary vascular
procedures. Upon introduction of a foreign material into the blood
stream, key proteins of the coagulation cascade (fibrinogen, and von
Willebrand’s factor) adsorb on the surface, followed by platelet adhesion
and activation, leading to fibrin and thrombus formation at the surface
(Figure 3.1).
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Figure 3.1: Illustration showing thrombus formation at the surface
of implantable medical devices. Upon exposure to blood, protein
adsorption occurs, followed by platelet adhesion at the surface.
Platelet activation leads to thrombus formation at the surface.
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An anti-coagulation regiment, with the adverse effects associated
with long term use, is typically required to clinically reduce the risk of
thrombus formation [5]. Thrombus formation involves two synergistic
events; a cGMP-dependant mechanism that involves platelet activation,
adhesion and aggregation [6], and fibrin formation resulting from the
binding of bivalent fibrinogen to glycoprotein IIb/IIIa [7].
Nitric oxide (NO), a molecule generated by the enzyme Nitric
Oxide Synthase [8], using L-arginine as a substrate, was recently
identified as a potent antiplatelet agent. This small molecule orchestrates
a myriad of vital physiological functions. For instance, the endotheliumderived NO production at low concentrations (nanomolar) plays a critical
role in the regulation of vascular hemostasis [9], and inhibits platelet
adhesion [10], and aggregation [11], as well as their further recruitment
to the growing thrombus [12]. There have been numerous reports
indicating NO release from resting [13] and aggregating platelets [14].
NO flux from activated human platelets have been indirectly measured
and is estimated at ~1.2 pmol.min-1/108 cells [13]. NO temporarily
inactivates platelets in the close proximity of the endothelium [15]. This
inhibition is short-lived and NO is rapidly scavenged by oxygen and
hemoglobin in plasma [16]. To maintain this vital function and
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counteract thrombus formation, stimulated human endothelial cells
continuously generate NO at a level of ca. 4x10-10 mol.cm-2 min-1 [17]. In
this regard, NO-releasing bio-polymers are targeted as effective antithrombotic coatings in an attempt to enhance thromboresistivity of
blood-contacting medical devices and implants.
Numerous approaches are investigated in an attempt to develop
polymeric materials that are more blood-compatible. In general, these
approaches can be categorized into two main trends: first, methods that
mimic the anti-thrombogenic properties of endothelial cells [18], and,
second, methods that use modified chemical surfaces and added moieties
that limit protein and cell adhesion [19]. Prevention of protein adhesion
in vivo is generally difficult to achieve, therefore the other approach,
which aims at the development of surfaces mimicking properties of
native endothelial cells, appears more promising. Nitric oxide,
thrombomodulin, prostacyclin, and heparans contribute to the nonthrombogenic properties of the endothelial cells [20]. A potential solution
can be found in polymeric coating materials that are capable of releasing
low levels of nitric oxide at the blood/coating interface. Considerable
efforts in this research area are focused on improving the NO-release
chemistry of materials used as outer coatings for implantable medical

63

devices. Polymers that possess chemical platforms with the ability of
releasing NO have been shown to exhibit varying levels of
thromboresistivity. In fact, akin to nitric oxide-releasing endothelial cells,
NO-releasing polymers as functional coatings have the potential to be
effective in preventing platelet adhesion, activation, and aggregation onto
surfaces. These coatings have the potential of reducing the risk of
thrombus formation at the exterior of blood-contacting devices and
implants. They also have the potential to prolong vascular graft and stent
potency without adverse systemic effects [21].
Two classes of NO-releasing materials have been explored. Ndiazeniumdiolate based NO-releasing polymers [22], and Nitrosothiolbased NO-releasing polymers [23]. N-diazeniumdiolates are inorganic
NO donors formed by the reaction of a secondary amine structure with 2
equivalents of NO gas under high pressure, creating a relatively stable
adduct structure [24]. The general structural types of diazeniumdiolates
used for NO-releasing polymers include dispersed non covalently bound
small molecules where the diazeniumdiolate group is attached to amines
in

low

molecular

weight

compounds,

and

covalently

bound

diazeniumdiolates group to polymeric side chains or to the polymeric
backbone [22].
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The second class of proposed NO donors are S-nitrosothiols [25]; they
mimic biological systems that are thought to serve as a NO reservoirs and
transporters, such as S-nitroso-albumin and S-nitrosoglutathione, which
are the most abundant naturally occurring S-nitrosothiols circulating in
blood [26].
While films made of NO-donors incorporated into polymeric
matrices did show the functional worthiness of NO-releasing coatings,
this approach naturally results in only finite NO reservoirs, and thus the
corresponding coatings are limited in their ability to sustain
antithrombotic function over prolonged periods of time. The finite NO
reservoir approach will also limit the potential use in more permanent
types of implants. In addition, the NO fluxes achieved so far are lower
than NO released from endothelial cells [19]. The logical alternative is
then to explore approaches that would lead to materials with the ability to
sustain NO generation for longer durations and at levels comparable to
stimulated human endothelial cells (ca. 4x10-10 molcm-2min-1) [17] and/or
potentially tunable levels.
Developing NO-releasing surfaces that closely resembles the
endothelium is critical to achieving better thromboresistivity. The
endothelial isoform of the enzyme nitric oxide synthase, eNOS, is a key
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component of the endothelial cell lining. It was reported that eNOSoverexpressing endothelial cells seeding of synthetic small diameter
vascular grafts decreased human platelet aggregation by 46%, and bovine
aortic smooth muscle cell proliferation by 67.2% in vitro [27]. NOreleasing materials using polyethyeleneimine (PEI), a biocompatible
polymer [28], has been reported in literature [29]. In our lab, NO was
successfully generated from the enzyme nitric oxide synthase embedded
in bilayered cast surfactant films [30].
In this work, we incorporated the enzyme nitric oxide synthase in the PEI
polymeric matrix by means of layer-by-layer electrostatic adsorption [8],
to construct a multicomponent protein film that mimics the NOgenerating behavior of the endothelial cell lining. We demonstrate in this
paper that our films provide a viable source of NO that utilizes
endogenous compounds to maintain a continuous supply of nitric oxide.
This study is the first account of successful NO release from the enzyme
nitric oxide synthase incorporated into a bio-polymeric matrix using a
LBL assembly technique. Our NO-releasing biopolymer coating is
successfully formed by alternate deposition of polyethyleneimine and
NO-generating NOS enzymes.
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3.2 RESULTS AND DISCUSSION

3.2.1 EXPRESSION AND PURIFICATION OF iNOSoxy VIA
RECOMBINANT PLASMID DNA

Many proteins and enzymes can be purchased through chemical
catalogs with moderate expense making them best procured through
those sources. NOS is not one of them. Because of the small biological
quantities found in animal tissue, preparation and purification from
biological sources would be prohibitively expensive. Making the
procurement even more prohibitive is the fact that we need to specifically
target the oxygenase domain of the enzyme, which could be obtained
separate from the reductase domain by limited proteolysis of the fulllength strand. However, to use NOS enzyme in the quantities required for
the completion of the current study requires an unbroken, relatively
inexpensive source of enzyme without the tedious extra steps involved
with enzyme proteolysis. This is accomplished through in-house protein
expression and purification of the oxygenase domain via recombinant
plasmid DNA.
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The pCWori vector, a generous gift from the laboratory of Dennis
Stuehr at the Lerner Research Institute, is inserted into plasmid DNA and
transformed into BL21 (DE3) ampicillin-resistant E. coli as detailed by
the Stuehr group [31]. This glycerol stock is then inoculated into 2 x 2 ml
LB medium with 100 µg/ml added ampicillin and allowed to grow
overnight at 37oC.
Each aliquot of overnight culture is added to 500 ml autoclaved
TB solution and allowed to grow under agitation at 37°C for about 3
hours or until 0.1 OD600 is reached. Temperature is dropped to 25°C until
0.3 – 0.8 OD600 is reached, at which time IPTG and δ-aminolevulinic acid
are added to induce iNOSoxy protein production and to provide a heme
precursor for the metalloprotein. The induced culture is left again
overnight to produce maximum quantities of protein. Cells are harvested
by centrifugation at 4,000 rpm at 4°C for 30 minutes, drained of
supernate, and resuspended in a minimum of pH 7.6 lysis buffer
containing

base

buffer,

lysozyme,

phenylmethanesulfonylfluoride

(PMSF), Protease Inhibitor III (4-(2-Aminoethyl) benzenesulfonyl
fluoride hydrochloride, aprotinin, leupetin, pepstatin A, bestatin, and L-3trans-Carboxyoxiran-2-carbonyl)-L-leucyl-agmatin), DNase, and MgCl2.
Cells are lysed by sonication at 15-second on, 45-second off intervals for
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a period of twenty minutes. The sonicated suspension is centrifugated at
12,000 g at 4°C for 30 minutes to precipitate cellular debris. The debris
pellet is discarded and the crude supernatant lysate is collected. Protein
precipitation is induced by gradual addition of 0.300 g (NH4)2SO4/ml of
solution over a period of 1 hour followed by centrifugation at 10,000 rpm
to collect the protein pellet. The pellet is again resuspended in base
buffer, PMSF, and Protease Inhibitor III and filtered through a 0.45
micron PES syringe filter.

A 4 ml dead volume Ni-NTA Agarose

column is prepared for use by charging with 50 mM NiSO4, followed by
addition of a binding tris buffer before loading the filtered protein sample
onto the column. The column is equilibrated with tris binding buffer and
washed with a dilute (40 mM) imidazole wash buffer prior to elution
with c. 200 mM imidazole elution buffer. The protein was collected off
the column and dialyzed in 500 ml base buffer with 200 µl βmercaptoethanol, changing dialysis solution twice during the overnight
process. The dialyzed protein is further concentrated by centrifugation at
5000 rpm at 4°C using 30,000 MW cut-off Amicon filters until the
desired concentration (usually 0.45 mM) is reached. Aliquots of the
protein are stored at -80°C for future use. Protein concentration is
determined by Bradford Assay and by UV-Vis analysis of the Soret band
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at 421 nm. SDS-PAGE further confirms the presence of iNOSoxy by
marker comparison to molecular weight standards.

3.2.2 PREPARATION OF PEI/NOSoxy FILM

We report here a proof of principle with the NOS oxygenase
domain. The tetrahydrobiopterin-free oxygenase domain of inducible
nitric oxide synthase (iNOSoxy) was expressed in house as reported in
literature [32], and was used to explore the viability of nitric oxide
synthase-containing films as potential sources of nitric oxide release.
Although other surfaces can be used for film formation, we describe here
the example of conductive pyrolytic graphite as a surface in order to
perform, in parallel, the electrochemical characterization of nitric oxide
synthase enzyme embedded in the polymetric film, as will be described
later. The pyrolytic graphite surface is initially chemically oxidized as
described in the literature to obtain a uniform negative charge at the
surface [33]. The negatively-charge surface is then alternatively dipcoated in polyethyleneimine (1.5 mg/ml) solution and iNOSoxy (20
mg/ml) solution for 20 minutes, respectively, to achieve the desired film
composition of 3 layers of iNOSoxy embedded in 4 alternate layers of
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PEI unless stated otherwise. The surface is thoroughly washed with
deionized water and air-dried after each dip-coating step. The films were
stored overnight at 4°C. (Figure 3.2)
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NOSoxy
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+1.5V-+1.7V

Figure 3.2: Assembly of PEI/NOSoxy film using layer-bylayer electrostatic deposition.
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3.2.3 FT-IR SPECTROSCOPIC CHARACTERIZATION

We first performed IR characterization of the iNOSoxy in PEI
films. Figure 3.3 shows the IR spectrum of iNOSoxy sandwished in
layers of PEI. The spectrum is focused in the amide-1 and amide-2 IR
region, which is often used to probe structural changes in globular
proteins. Figure 1 shows that the overall shapes and positions of the two
amide-bands are conserved in PEI films compared to native iNOSoxy in
the absence of PEI. This result shows that the iNOSoxy conserves its
major globular structure features in the PEI thin film.
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Figure 3.3: Infrared spectrum in the amide I and amide II IR region
showing that these bands, as spectroscopic probes of the NOSoxy
structure in the PEI film, are conserved.
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3.2.4 ELECTROCHEMICAL CHARACTERIZATION

To characterize the functional integrity of iNOSoxy embedded in
the PEI film, we examined the electrochemical reduction of NO by
iNOSoxy in film at the surface of pyrolytic graphite electrodes. The
experiments for the characterization of NOS functional integrity using
NO are carried out in the absence of oxygen. For these experiments only,
the buffer is typically purged with purified nitrogen for at least 30 min
prior to the experiments. A nitrogen blanket was then kept over the
solution throughout the experiments. A fresh solution of 2mM NO was
prepared, and required aliquots are added to the solution to make the
desired concentration increments. NO stock-solutions are made by
bubbling pure NO gas through degassed water [34]. NOSoxy enzymes,
like other heme proteins and P-450 enzymes, can catalyze the
electrochemical reduction of the nitric oxide as a substrate [35, 36]. We
used this known property to characterize the presence and function of
iNOSoxy enzymes embedded between the PEI layers in our thin films.
Cyclic voltammetry of PEI/iNOSoxy film at the surface of PG electrodes
(Figure 3.4) illustrates an irreversible catalytic wave at –0.9V/s, a
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response typical to the catalytic reduction of NO by a heme protein such
as iNOSoxy [35, 36].
A negative control experiment (PEI film devoid of iNOSoxy),
does not show a catalytic current at –0.9V/s at the same NO
concentrations (Figure 3.5). The increase in catalytic currents at –0.9V/s
upon incremental additions of NO is a clear indication of iNOSoxy
catalytic mediation, and further confirms that its structural integrity and
catalytic function are preserved in the in our PEI films. The native
structure and integrity of embedded NOS enzyme and related enzymatic
function are critical to the successful fabrication of our targeted NOSbased NO-releasing films.
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Figure 3.4: Cyclic voltammograms of catalytic reductions of NO by
PEI/NOS films at the surface of a PG electrode in pH 7.0 for different
NO concentrations. The film on the electrode was formed by the alternate
deposition of 5 layers of NOS enzyme sandwiched between PEI layers.
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Figure 3.5: Negative control showing no catalytic reduction of NO on
PEI films devoid of iNOSoxy protein
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3.2.5 ATOMIC FORCE MICROSCOPY

To investigate the success of our methodology in producing
polymeric film coatings with the desired coverage and surface
morphology, we further characterized our LBL deposition of film
components using atomic force microscopy (AFM) imaging. Figure 3.6
illustrates the AFM image of the layer-by-layer iNOSoxy/PEI film
buildup. Figure 3.6A shows the 3D AFM image of the deposition of a
layer of iNOSoxy over a layer of the polymer PEI at the surface of the
HOPG slide. The figure shows a uniform distribution of the enzyme over
the surface. Closer analysis of the features that result upon exposure to
iNOSoxy solution confirms that the observed dimensions are close to the
crystallographic dimension of iNOSoxy [37]. The overall surface height
is of the order of 70 Å. Figure 3.6B shows the AFM image of the same
HOPG slide after the sequential deposition of PEI over a layer of
iNOSoxy resulting in the PEI/iNOSoxy/PEI coating. This image shows
that the layer of iNOSoxy is still present but is now embedded in
between two alternate PEI layers. The biocompatible polymeric coat now
brings the average surface height to the order of 80 Å, which is consistent
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with the cumulative surface heights measured for the PEI layers an the
layer of iNOSoxy.
Our step-by-step AFM characterization shows that the functional
component of our films, i.e. the iNOSoxy enzyme, is successfully
trapped in between layers of the PEI polymer. In addition, AFM imaging
shows that our LBL methodology yields a thin film with uniform
coverage of the surface. A uniform coverage of the surface is key for
efficiently prohibiting seed contacts at the blood/device interface, which
will help improve the thromboresistivity of the device.
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Figure 3.6: Atomic force microscopy images at the surface of highly
oriented pyrolytic graphite (HOPG) depicting typical PEI/NOS film
composition. (A) is a 2µmx2µm 3D scan of a layer of NOS enzyme
deposited over a layer of PEI polymer. (B) is µmx2µm 3D scan of the
final layer of PEI polymer deposited after the deposition of a NOS
enzyme layer.
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3.2.6

QUARTZ

CRYSTAL

MICROBALANCE

(QCM)

CHARACTERIZATION

Quartz Crystal Microbalance (QCM) was used as a tool to
investigate mass changes upon the alternate deposition of PEI and the
NOSoxy enzyme. QCM analysis was carried out at the surface of a thin
oscillating quartz crystal sandwiched between two gold electrodes. The
measurement of the resonant frequency changes at the surface of a
modified quartz crystal with the alternate deposition of PEI and iNOSoxy
at the surface of a quartz crystal indicates a decrease in frequency that
correlates with mass increase at the surface. Figure 3.7A indicates a
typical QCM plot of the frequency change ∆F0 upon the alternate
deposition of PEI and the NOS enzyme on a quartz crystal. The average
change in frequency per layer deposited is ∆F0= 120 Hz as indicated by
Figure 3.7A.
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Figure 3.7: A- Monitoring of the PEI/NOS multilayer film building
through

the

layer-by-layer

methodology

using

quartz

crystal

microbalance. B- Proposed model based on measured changes in crystal
frequency showing that iNOSoxy in a monolayer of double-stack
(vertical) dimers in each layer of iNOSoxy in the LBL process.
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The change in frequency can be converted to mass changes by the
Sauerbrey equation [38]. The mass change obtained in addition to the
known dimensions of the iNOSoxy enzyme (60x50x40 Å), and the
molecular weight of the iNOSoxy (60kDa) allows the determination of a
model of the enzyme orientation within the PEI film. A monolayer of
double-stacked iNOSoxy dimers (as seen in Figure 3.7B) corresponds to
a theoretical ∆F0= 118 Hz which is of the same magnitude as the ∆F0
seen experimentally. iNOSoxy is catalytically active in the dimeric form
hence indicating that the charge-dependant orientation of the enzyme
within the PEI matrix is such to retain its function.

3.2.7 NITRIC OXIDE FLUX MEASUREMENTS

Successful NO release was achieved from our PEI/NOS films and
at fluxes higher than what have been reported in the literature for other
inorganic NO-releasing systems [19]. Typical substrates prepared as
described above are utilized to investigate the NO production capability
from the trapped iNOSoxy enzymes. For the flux measurement of NO
released from the NOS/PEI films, we used a reaction cocktail composed
of the intermediate N-hydroxy-L-arginine (NHA; 100µM) [39],
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tethrahydrobiopterin (H4B; 10µM), Dithiothreitol (DTT; 400µM) in
phosphate buffer (100mM; pH=7.4). Hydrogen peroxide (H2O2) was
used as a source of reducing equivalents in the known NOS peroxide
shunt reaction. The enzymatic reaction was run at 37°C for the desired
time period. The enzymatic activity of the PEI/NOS film was quantified
by measuring NO released using the Griess assay [40] which tracks the
accumulation of nitrite as the decomposition product of NO generated by
iNOSoxy in the film. Figure 3.8 reveals total NO release from films
composed of 3 consecutive layers of PEI/NOS. An increase in NO
released is achieved with increasing time.
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Figure 3.8: Total surface NO flux from PEI/NOS preparation as
determined by the Griess assay. The PEI/NOS film is composed of 3
layers of NOS enzyme sandwiched between alternate PEI polymer
layers. n=6
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Figure 3.9: NO surface flux vs time from PEI/NOS preparation as
determined by the Griess assay. The PEI/NOS film is composed of 3
layers of NOS enzyme sandwiched between alternate PEI polymer
layers. n=6
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Figure 3.9 shows the cumulative NO production by the
(PEI/iNOSoxy) coating in terms of normalized NO surface flux. The
figure shows that an initial burst of NO occurs at ~2 hours (6.377x10-10
moles NO.min-1.cm-2 ± 0.523; n=6), 4 hours (3.611x10-10 moles NO.min1

.cm-2 ± 0.177; n=6), 8 hours (1.913x10-10 moles NO.min-1.cm-2 ± 0.148;

n=6), followed by a sustained release at 24 hours (0.707x10-10 moles
NO.min-1.cm-2 ± 0.08; n=6), and 48 hours (0.511x10-10 moles NO.min1

.cm-2 ± 0.088; n=6). Successful NO release was achieved from our

PEI/NOS films and at fluxes higher than what have been reported in the
literature

for

other

inorganic

NO-releasing

systems.[19]

Our

PEI/iNOSoxy film sustained catalytic production of NO for long periods
of time and in conditions that mimic physiologic settings. This proof of
concept based on using NOS oxygenase domain shows that the enzyme,
although trapped in the polymeric matrix, is still accessible by the Nhydroxy-L-arginine as a substrate surrogate and hydrogen peroxide as a
source of electrons in solution. Nitric oxide is produced as a result of the
NOSoxy-mediated catalytic oxidation of N-hydroxy-L-arginine. Our
enzyme-based NO production approach in the biocompatible PEI film
closely mimics the behavior of endothelial cells and essentially
overcomes the shortcoming of other approaches that result in only finite
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NO-reservoirs. Sustained NO fluxes were observed for a period of 72
hours. NO fluxes at 2 hours (6.377x10-10 molesNO.min-1.cm-2) are 150
fold higher than fluxes from stimulated human endothelial cells (4x10-10
mol.min-1.cm-2).[17] This initial burst eventually settles down at longer
periods. For instance, the average NO flux at 48 hours is around only
(0.511x10-10 molesNO.min-1.cm-2), a value that is still ten-fold higher
than NO fluxes from stimulated human endothelial cells. In addition,
they are over 1000-fold higher than NO released from platelets.[13] NO
release from PEI films shows 2-phase kinetics: an initial burst of NO,
followed by a sustained release over a longer period of time. This 2phase kinetics of NO release is in line with previously published
studies.[41] The initial burst can be useful to counter early prosthetic
graft occlusion that occurs in 18% of synthetic vascular access conduits
for dialysis [42], and 25% of infrapoliteal synthetic grafts.[3] The
PEI/NOS film has the ability to function as a thromboresistant scaffold
that imitates the endothelial cell lining response through the biphasic NO
release exhibited.
To monitor the effects of film thickness on NO fluxes we
investigated NO release from films with varying numbers of iNOSoxy
layers. Figure 3.10 shows increased NO fluxes from a film composed of
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5 layers of PEI/NOS relative to a film preparation of 3 layers of
PEI/NOS, indicating that higher NO fluxes can be achieved by increasing
the thickness, i.e. enzyme loading, of the polymeric coatings. The rate of
NO release is crucial, and the optimum NO levels for coatings to be
applied on medical devices and blood-contacting implants are yet to be
determined. Therefore, the ability to control NO fluxes is of utmost
importance. Our layer-by-layer approach provides the ability to control
NO fluxes from films by varying the number of NOS enzyme layers in
the polymeric matrix. In addition to producing nanometer-thick coatings,
the layer-by-layer electrostatic self-assembly method has the built-in
ability to tweak the film architecture to meet the requirements of
thickness and composition.
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Figure 3.10: NO fluxes from PEI/NOS films with various thicknesses as
determined by the Griess assay. The PEI/NOS film is composed of 3 and
5 layers of NOS enzyme sandwiched between alternate PEI polymer
layers; time= 2hrs & 4hrs
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Our results with 3 and 5 PEI/NOSoxy layers show that fluxes of NO
release correlate with the number of enzyme layers present in the film.
Increasing the number of iNOSoxy layers deposited within the PEI film
yields higher NO fluxes, indicating the ability of our approach to finetune NO fluxes to meet requirements of optimum release for varying
applications. This work shows a proof of principle strategy to use NOS
enzymes in biocompatible films to release NO. These functional films
would thus counteract thrombosis on blood-contacting devices. A similar
work using the full length NOS with its reductase and oxygenase
domains will be presented in the next chapter and show that NO can be
similarly produced using the substrate arginine and the native NADPH as
a source of electrons.

3.3 CONCLUSIONS
We have presented a proof of principle of a new approach for
making antithrombotic coatings for medical devices and implants based
on NO release. Our alternative approach is based on using nitric oxide
synthase enzyme as the functional unit in a polymeric film for catalytic
production of NO. The approach can use endogenous compounds for
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continuous NO release from biocompatible films under physiologic
conditions. We have demonstrated that NOS-based polymetric films
successfully generate NO under physiologic condition at levels higher
than those observed for endothelial cells. The level of NO release can be
tuned through varying the number of NOS layers in the film buildup. We
have shown that NO fluxes from our NOS-based PEI films are sustained
for prolonged periods of time, which has the potential of producing
efficient, long-term, antithrombotic coatings for medical devices and
blood-contacting tools such as stents and catheters.
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CHAPTER IV
NO-RELEASE NITRIC OXIDE SYNTHASE-BASED
BIOPOLYMERS

4.1 INTRODUCTION
Graft thrombosis is the cause of 80% of vascular access dysfunction, a
problem with an associated health-care cost of over $1 billion/year [1].
The number of revascularization procedures have increased dramatically,
and is estimated at 15% after initial coronary revascularization, and
approximately 50% after lower extremity bypass [2,3]. Stent restenosis
occurs at 30% of implant sites as a result of initial vascular thrombosis
followed by cell proliferation, requiring a repeat angioplasty procedure
within 1 year [4].
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The thrombogenic nature of various polymeric materials utilized to
prepare blood-contacting and implantable medical devices such as
vascular grafts, intravascular catheters, sensors, coronary artery and
vascular stents, and a host of other medical tools, even if labeled as
biocompatible, can cause serious complications in patients. Thrombus
formation at the surface of implantable medical devices is the major
cause of vascular access dysfunction requiring secondary vascular
procedures. Upon introduction of a foreign material into the blood
stream, key proteins of the coagulation cascade (fibrinogen, and von
Willebrand’s factor) adsorb on the surface, followed by platelet adhesion
and activation, leading to fibrin and thrombus formation at the surface
(Figure 4.1).
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Figure 4.1: Illustration showing thrombus formation at the surface
of implantable medical devices. Upon exposure to blood, protein
adsorption occurs, followed by platelet adhesion at the surface.
Platelet activation leads to thrombus formation at the surface.
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An anti-coagulation regiment, with the adverse effects associated
with long term use, is typically required to clinically reduce the risk of
thrombus formation [5]. Thrombus formation involves two synergistic
events; a cGMP-dependant mechanism that involves platelet activation,
adhesion and aggregation [6], and fibrin formation resulting from the
binding of bivalent fibrinogen to glycoprotein IIb/IIIa [7].
Nitric oxide (NO), a molecule generated by the enzyme Nitric
Oxide Synthase (NOS) using L-arginine as a substrate, was recently
identified as a potent antiplatelet agent. This small molecule orchestrates
a myriad of vital physiological functions. For instance, the endotheliumderived NO production at low concentrations (nanomolar) plays a critical
role in the regulation of vascular hemostasis [8], and inhibits platelet
adhesion [9], and aggregation [10], as well as their further recruitment to
the growing thrombus [11]. There have been numerous reports indicating
NO release from resting [12], and aggregating platelets [13]. NO flux
from activated human platelets have been indirectly measured and is
estimated at ~1.2 pmol.min-1/108 cells [12]. NO temporarily inactivates
platelets in the close proximity of the endothelium [14]. This inhibition is
short-lived and NO is rapidly scavenged by oxygen and hemoglobin in
plasma [15]. To maintain this vital function and counteract thrombus
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formation, stimulated human endothelial cells continuously generate NO
at a level of ca. 4x10-10 mol.cm-2 min-1 [16]. In this regard, NO-releasing
bio-polymers are targeted as effective anti-thrombotic coatings in an
attempt to enhance thromboresistivity of blood-contacting medical
devices and implants.
Numerous approaches are investigated in an attempt to develop
polymeric materials that are more blood-compatible. In general, these
approaches can be categorized into two main trends: first, methods that
mimic the anti-thrombogenic properties of endothelial cells [17], and,
second, methods that use modified chemical surfaces and added moieties
that limit protein and cell adhesion [18]. Prevention of protein adhesion
in vivo is generally difficult to achieve, therefore the other approach,
which aims at the development of surfaces mimicking properties of
native endothelial cells, appears more promising. Nitric oxide,
thrombomodulin, prostacyclin, and heparans contribute to the nonthrombogenic properties of the endothelial cells [19]. A potential solution
can be found in polymeric coating materials that are capable of releasing
low levels of nitric oxide at the blood/coating interface. Considerable
efforts in this research area are focused on improving the NO-release
chemistry of materials used as outer coatings for implantable medical
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devices. Polymers that possess chemical platforms with the ability of
releasing NO have been shown to exhibit varying levels of
thromboresistivity. In fact, akin to nitric oxide-releasing endothelial cells,
NO-releasing polymers as functional coatings have the potential to be
effective in preventing platelet adhesion, activation, and aggregation onto
surfaces. These coatings have the potential of reducing the risk of
thrombus formation at the exterior of blood-contacting devices and
implants. They also have the potential to prolong vascular graft and stent
potency without adverse systemic effects [20]
Two classes of NO-releasing materials have been explored. Ndiazeniumdiolate based NO-releasing polymers [21], and Nitrosothiolbased NO-releasing polymers [22]. N-diazeniumdiolates are inorganic
NO donors formed by the reaction of a secondary amine structure with 2
equivalents of NO gas under high pressure, creating a relatively stable
adduct structure [23]. The general structural types of diazeniumdiolates
used for NO-releasing polymers include dispersed non covalently bound
small molecules where the diazeniumdiolate group is attached to amines
in

low

molecular

weight

compounds,

and

covalently

bound

diazeniumdiolates group to polymeric side chains or to the polymeric
backbone [21].
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The second class of proposed NO donors are S-nitrosothiols [24]; they
mimic biological systems that are thought to serve as a NO reservoirs and
transporters, such as S-nitroso-albumin and S-nitrosoglutathione, which
are the most abundant naturally occurring S-nitrosothiols circulating in
blood [25].
While films made of NO-donors incorporated into polymeric
matrices did show the functional worthiness of NO-releasing coatings,
this approach naturally results in only finite NO reservoirs, and thus the
corresponding coatings are limited in their ability to sustain
antithrombotic function over prolonged periods of time. The finite NO
reservoir approach will also limit the potential use in more permanent
types of implants. In addition, the NO fluxes achieved so far are lower
than NO released from endothelial cells [18]. The logical alternative is
then to explore approaches that would lead to materials with the ability to
sustain NO generation for longer durations and at levels comparable to
stimulated human endothelial cells (ca. 4x10-10 molcm-2min-1) [16],
and/or potentially tunable levels.
Developing NO-releasing surfaces that closely resembles the
endothelium is critical to achieving better thromboresistivity. The
endothelial isoform of the enzyme nitric oxide synthase, eNOS, is a key
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component of the endothelial cell lining. It was reported that eNOSoverexpressing endothelial cells seeding of synthetic small diameter
vascular grafts decreased human platelet aggregation by 46%, and bovine
aortic smooth muscle cell proliferation by 67.2% in vitro [26]. NOreleasing materials using polyethyeleneimine (PEI), a biocompatible
polymer [27], has been reported in literature [28]. In our lab, NO was
successfully generated from the enzyme nitric oxide synthase embedded
in bilayered cast surfactant films [29].
NO releasing materials using Polyethyeleneimine (PEI), a biocompatible
polymer [27], has been reported in literature [28,30,31]. In our lab, NO
was successfully generated nitric oxide from the oxygenase domain of
the enzyme Nitric Oxide Synthase (NOSoxy) embedded in polymeric
matrix by means of layer-by-layer electrostatic adsorption [32,33]. In this
work, we incorporated the enzyme nitric oxide synthase in the PEI
polymeric matrix by means of layer-by-layer electrostatic adsorption
[33], to construct a multicomponent protein film that mimics the NOgenerating behavior of the endothelial cell lining. We demonstrate in this
paper that our films provide a viable source of NO that utilizes
endogenous compounds to maintain a continuous supply of nitric oxide.
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4.2 MATERIALS AND METHODS

4.2.1

EXPRESSION AND PURIFICATION OF iNOS VIA
RECOMBINANT PLASMID DNA

Many proteins and enzymes can be purchased through chemical
catalogs with moderate expense making them best procured through
those sources. NOS is not one of them. Because of the small biological
quantities found in animal tissue, preparation and purification from
biological sources would be prohibitively expensive. Making the
procurement even more prohibitive is the fact that we need to specifically
target the oxygenase domain of the enzyme, which could be obtained
separate from the reductase domain by limited proteolysis of the fulllength strand. However, to use NOS enzyme in the quantities required for
the completion of the current study requires an unbroken, relatively
inexpensive source of enzyme without the tedious extra steps involved
with enzyme proteolysis. This is accomplished through in-house protein
expression and purification of the full-length enzyme via recombinant
plasmid DNA.
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The pCWori vector, a generous gift from the laboratory of Dennis
Stuehr at the Lerner Research Institute, is inserted into plasmid DNA and
transformed into BL21 (DE3) ampicillin-resistant E. coli as detailed by
the Stuehr group [34]. This glycerol stock is then inoculated into 2 x 2 ml
LB medium with 100 µg/ml added ampicillin and chloramphenicol, and
allowed to grow overnight at 37oC.
Each aliquot of overnight culture is added to 500 ml autoclaved
TB solution and allowed to grow under agitation at 37°C for about 3
hours or until 0.1 OD600 is reached. Temperature is dropped to 25°C until
0.3 – 0.8 OD600 is reached, at which time IPTG and δ-aminolevulinic acid
are added to induce iNOS protein production and to provide a heme
precursor for the metalloprotein. The induced culture is left again
overnight to produce maximum quantities of protein. Cells are harvested
by centrifugation at 4,000 rpm at 4°C for 30 minutes, drained of
supernate, and resuspended in a minimum of pH 7.6 lysis buffer
containing

base

buffer,

lysozyme,

phenylmethanesulfonylfluoride

(PMSF), Protease Inhibitor III (4-(2-Aminoethyl) benzenesulfonyl
fluoride hydrochloride, aprotinin, leupetin, pepstatin A, bestatin, and L-3trans-Carboxyoxiran-2-carbonyl)-L-leucyl-agmatin), DNase, and MgCl2.
Cells are lysed by sonication at 15-second on, 45-second off intervals for
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a period of twenty minutes. The sonicated suspension is centrifugated at
12,000 g at 4°C for 30 minutes to precipitate cellular debris. The debris
pellet is discarded and the crude supernatant lysate is collected. Protein
precipitation is induced by gradual addition of 0.300 g (NH4)2SO4/ml
over a period of 1 hour followed by centrifugation at 10,000 rpm to
collect the protein pellet. The pellet is again resuspended in base buffer,
PMSF, and Protease Inhibitor III and filtered through a 0.45 micron PES
syringe filter. A 4 ml dead volume Ni-NTA Agarose column is prepared
for use by charging with 50 mM NiSO4, followed by addition of a
binding tris buffer before loading the filtered protein sample onto the
column. The column is equilibrated with tris binding buffer and washed
with a dilute (40 mM) imidazole wash buffer prior to elution with c. 200
mM imidazole elution buffer. The protein was collected off the column
and dialyzed in 500 ml base buffer with 200 µl β-mercaptoethanol,
changing dialysis solution twice during the overnight process. The
dialyzed protein is further concentrated by centrifugation at 5000 rpm at
4°C using 30,000 MW cut-off Amicon filters until the desired
concentration (usually 0.45 mM) is reached. Aliquots of the protein are
stored at -80°C for future use. Protein concentration is determined by
Bradford assay and by UV-Vis analysis of the Soret band at 421 nm.
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SDS-PAGE further confirms the presence of iNOS by marker
comparison to molecular weight standards.

4.2.2 PREPARATION OF PEI/NOS FILM

The full length inducible nitric oxide synthase (iNOS) was
expressed in house as reported in literature [35]. A pyrolytic graphite
surface (unless indicated otherwise) was initially modified utilizing our
diazonium method as described in the literature to obtain a uniform
negative charge at the surface [36]. Typically, the PG surface is dipped in
a mixture of 50mM p-aminobenzoate and 50mM sodium nitrite at 4˚C, in
a 3 necked electrochemical cell. The potential is scanned between 0 and 0.6 V vs Ag/AgCl leading to the covalent attachment of diazonium group
on the surface, with a free carboxylic group (COO-). The pyrolytic
graphite surface was alternatively dipped coated in a polyethyleneimine
(PEI; 1.5mg/ml) solution and iNOS solution for 10 minutes respectively
to achieve the desired film composition. The surface was thoroughly
washed with deionized and air-dried after each step. The films were
stored overnight at 4°C. (Figure 4.2)
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2.5%K2Cr2O7

PEI1.5mg/ml

NOSoxy

PEI1.5mg/ml

+1.5V-+1.7V

Figure 4.2: Assembly of PEI/NOS film using layer-by-layer
electrostatic deposition.
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4.2.3

QUARTZ

CRYSTAL

MICROBALANCE

(QCM)

CHARACTERIZATION

QCM analysis was carried out at the surface of a thin oscillating
quartz crystal sandwiched between two gold electrodes. Prior to coating,
the quartz crystal surface surface was cleaned by soaking in a piranha
solution (30%H2O2; 70%H2SO4) for 5 minutes, followed by rinsing with
deionized water, and dried under nitrogen. The surface of the quartz
crystal was modified, prior to deposition, with our diazonium method as
previously described. We measured the reduction in resonance frequency
with each deposited layer and calculated the mass deposited using the
Sauerbrey equation, which directly relates the decrease in frequency to
mass change [37]. QCM analysis was performed on a CH Instrument
electrochemical workstation using a QCM cell; the same cell was used
for electrochemical experiments needed to modify the gold surface prior
to LBL depositions.
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4.2.4 ATOMIC FORCE MICROSCOPY

Atomic Force Microscopy characterization was carried out at the
surface of 1cmx1cm highly oriented pyrolytic graphite (HOPG) slides.
Initially, the top layer on the slide was peeled to eliminate any
interference from dust particles. The HOPG surface was modified with
the diazonium method as previously described. The surface was modified
as previously described and images were taken following each layer
deposition using a Molecular Imaging pico-SPM using the MAC mode
interfaced with a PicoScan controller (MICorp, Arizona).

4.2.5 NO FLUX MEASUREMENTS

The films were prepared as described above. We prepared reaction
cocktail composed of the substrate L-arginine at physiological levels
(100µM) [38], 1mM Calcium Chloride (CaCl2) in Phosphate buffer
(100mM; pH=7.4). NADPH (150µM) was used as a source of reducing
equivalents, which is widely used in the NOS community. The enzymatic
reaction was run at 37°C for the desired time period. The enzymatic
activity of the film at the pyrolytic graphite surface was quantified by
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measuring NO flux using the Griess assay [39,40]. Absorbance
measurements were taken using an Agilent 8543 Spectrophotometer
utilizing 1-cm path UV-visible cells.

4.2.6 PLATELET ADHESION STUDIES

Whole blood from dog was drawn into blood collection tubes
containing 60 units of sodium heparin as an anticoagulant. The
heparinized whole blood was centrifuged at 110g for 15 min at 228C.
platelet-rich plasma (PRP) was collected from the supernatant. To reestablish platelet activity, CaCl2 was added to the PRP to raise [Ca2+] by
2 mM. Before PRP incubation, the Indium Tin Oxide (ITO) slides were
modified by the method described previously. Then, the polymer coated
ITO slides were incubated for 1 h at 37˚C in 500 mL of recalcified PRP
under static conditions. The PRP was then decanted and the wells were
washed once with 200 mL PBS.
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4.2.7 LACTATE DEHYDROGENASE ASSAY

Before PRP incubation, the poly-L-Lysine coated microtiter plate
wells were modified by the method described previously. Then, 100 mL
of recalcified PRP was added to each polymer-coated well and incubated
for 1 h at 37˚C under static conditions. The PRP was then decanted and
the wells were washed once with 200 mL PBS. Adhered platelets were
lysed using a lysing buffer which was 1% (w/v) Triton X-100. 150µL of
lysing buffer was incubated in each well for 1 h at 37˚C with occasional
agitation to completely disrupt the platelet membranes. Then, 100 µL of
each lysate solution was pipetted into wells of a 96-well polystyrene
microtiter plate (Fisher) that contained 100 µL of reagent from an LDH
assay kit (Roche Applied Sciences, Indianapolis, IN), and incubated for
30 min at 25˚C. Then, 50 µL of stop solution is added and absorbance of
each well at 490 nm was monitored by a Labsystems Multiskan RC
microplate reader.
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4.3 RESULTS AND DISCUSSION

4.3.1

QUARTZ

CRYSTAL

MICROBALANCE

(QCM)

CHARACTERIZATION

Quartz Crystal Microbalance (QCM) was used as a tool to
investigate mass changes upon the alternate deposition of PEI and the
iNOS enzyme. QCM analysis was carried out at the surface of a thin
oscillating quartz crystal sandwiched between two gold electrodes. The
measurement of the resonant frequency changes at the surface of a
modified quartz crystal with the alternate deposition of PEI and iNOS at
the surface of a quartz crystal indicates a decrease in frequency that
correlates with mass increase at the surface. Figure 4.4 indicates a typical
QCM plot of the frequency change ∆F0 upon the alternate deposition of
PEI and the NOS enzyme on a quartz crystal. The average change in
frequency per layer deposited is ∆F0= 58 Hz as indicated by Figure 4.3.
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Figure 4.3: A- Monitoring of the PEI/NOS multilayer film building
through

the

layer-by-layer

methodology

using

quartz

crystal

microbalance. B- Proposed model based on measured changes in crystal
frequency showing that iNOSoxy in a monolayer of dimers in each layer
of iNOSoxy in the LBL process.
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The change in frequency can be converted to mass changes by the
Sauerbrey equation [37]. The mass change obtained in addition to the
known dimensions of the iNOS enzyme (120x80x60 Å), and the
molecular weight of the iNOS (120kDa) allows the determination of a
model of the enzyme orientation within the PEI film. A monolayer of
iNOS dimers (as seen in Figure 4.3B) corresponds to a theoretical ∆F0=
60 Hz which is of the same magnitude as the ∆F0 seen experimentally.
iNOS is catalytically active in the dimeric form hence indicating that the
charge-dependant orientation of the enzyme within the PEI matrix is such
to retain its function.

4.3.2 ATOMIC FORCE MICROSCOPY CHARACTERIZATION

To investigate the success of our methodology in producing
polymeric film coatings with the desired coverage and surface
morphology, we further characterized our LBL deposition of film
components using atomic force microscopy (AFM) imaging. Figure 4.4
illustrates the AFM image of the layer-by-layer iNOS/PEI film buildup.
Figure 4.4A illustrates the 3D AFM image of the deposition of a layer of
the polymer PEI at the surface of the HOPG slide. The figure shows a
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uniform spread of the PEI polymer on the surface. The surface height is
of the order of 2.0nm. Figure 4.4B shows the 3D AFM image of the
deposition of a layer of iNOS over a layer of the polymer PEI at the
surface of the HOPG slide. The figure shows a uniform distribution of
the enzyme over the surface. Closer analysis of the features that result
upon exposure to iNOS solution confirms that the observed dimensions
are close to the crystallographic dimension of iNOS [42]. The overall
surface height is of the order of 8.0nm. Figure 4.4C shows the AFM
image of the same HOPG slide after the sequential deposition of PEI over
a layer of iNOS resulting in the PEI/iNOS/PEI coating. This image shows
that the layer of iNOS is still present but is now embedded in between
two alternate PEI layers. The biocompatible polymeric coat now brings
the average surface height to the order of 10.0nm, which is consistent
with the cumulative surface heights measured for the PEI layers an the
layer of iNOS.
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A

B

C

FIGURE 4.4: Atomic force microscopy images at the surface of highly
oriented pyrolytic graphite (HOPG) depicting typical PEI/NOS film
composition. (A) is a 2µmx2µm 3D scan of the layer of PEI polymer
deposited at the HOPG surface. (B) is a 2µmx2µm 3D scan of a layer of
NOS enzyme deposited over a layer of PEI polymer. (C) is a 2µmx2µm
3D scan of the final layer of PEI polymer deposited after the deposition
of a NOS enzyme layer.
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Our step-by-step AFM characterization shows that the
functional component of our films, i.e. the iNOS enzyme, is successfully
trapped in between layers of the PEI polymer. In addition, AFM imaging
shows that our LBL methodology yields a thin film with uniform
coverage of the surface. A uniform coverage of the surface is
instrumental in efficiently prohibiting seed contacts at the blood/device
interface, which will help improve the thromboresistivity of the device.

4.3.3 NO FLUX MEASUREMENTS
Successful NO release was achieved from our PEI/NOS films and
at fluxes higher than what have been reported in the literature for other
inorganic NO-releasing systems [18]. Typical substrates prepared as
described above are utilized to investigate the NO production capability
from the trapped iNOS enzymes. The enzymatic activity of the coatings
at the pyrolytic graphite surface was quantified by measuring NO flux
using the Griess assay [39, 40], which tracks the accumulation of nitrite
as the decomposition product of NO generated by iNOS in the film.
Figure 4.5 reveals total NO release from films composed of 5 consecutive
layers of PEI/NOS. An increase in NO released is achieved with
increasing time.
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Figure 4.5: Total surface NO flux from PEI/NOS preparation as
determined by the Griess assay. The PEI/NOS film is composed of 5
layers of NOS enzyme sandwiched between alternate PEI polymer
layers. n=5
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Figure 4.6 shows the cumulative NO production by the (PEI/iNOS)
coating in terms of normalized NO surface flux. The figure shows that an
initial burst of NO occurs at 24 hours (1.09nM NO.min-1.cm-2 ± 0.45;
n=5), 48 hours (0.88nM NO.min-1.cm-2 ± 0.13; n=6), 72 hours (0.59nM
NO.min-1.cm-2 ± 0.08; n=5), followed by a sustained release at 96 hours
(0.54nM NO.min-1.cm-2 ± 0.12; n=5).
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Figure 4.6: NO surface flux vs time from PEI/NOS preparation as
determined by the Griess assay. The PEI/NOS film is composed of 3
layers of NOS enzyme sandwiched between alternate PEI polymer
layers. n=5
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Successful NO release was achieved from our PEI/NOS films and
at fluxes higher than what have been reported in the literature for other
inorganic NO-releasing systems [18]. Our PEI/iNOS film sustained
catalytic production of NO for long periods of time and in conditions that
mimic physiologic settings. Our enzyme-based NO production approach
in the biocompatible PEI film closely mimics the behavior of endothelial
cells and essentially overcomes the shortcoming of other approaches that
result in only finite NO-reservoirs. Sustained NO fluxes were observed
for a period of 96 hours. This initial burst eventually settles down at
longer periods. NO release from PEI films shows 2-phase kinetics: an
initial burst of NO, followed by a sustained release over a longer period
of time. This 2-phase kinetics of NO release is in line with previously
published studies [43]. The initial burst can be useful to counter early
prosthetic graft occlusion that occurs in 18% of synthetic vascular access
conduits for dialysis [44], and 25% of infrapoliteal synthetic grafts [3].
The PEI/NOS film has the ability to function as a thromboresistant
scaffold that imitates the endothelial cell lining response through the
biphasic NO release exhibited.

126

To monitor the effects of film thickness on NO fluxes we
investigated NO release from films with varying numbers of iNOS
layers. Figure 4.7 shows increased NO fluxes from a film composed of 5
layers of PEI/NOS relative to a film preparation of 3 layers, and 1 layer
of PEI/NOS respectively, indicating that higher NO fluxes can be
achieved by increasing the thickness, i.e. enzyme loading, of the
polymeric coatings. The rate of NO release is crucial, and the optimum
NO levels for coatings to be applied on medical devices and bloodcontacting implants are yet to be determined. Therefore, the ability to
control NO fluxes is of utmost importance. Our layer-by-layer approach
provides the ability to control NO fluxes from films by varying the
number of NOS enzyme layers in the polymeric matrix. In addition to
producing nanometer-thick coatings, the layer-by-layer electrostatic selfassembly method has the built-in ability to tweak the film architecture to
meet the requirements of thickness and composition.
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Figure 4.7: NO fluxes from PEI/NOS films with various thicknesses as
determined by the Griess assay. The PEI/NOS film is composed of 1,3
and 5 layers of NOS enzyme sandwiched between alternate PEI polymer
layers; time= 8hrs
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Our results with 1, 3 and 5 PEI/NOS layers show that fluxes of NO
release correlate with the number of enzyme layers present in the film.
Increasing the number of iNOS layers deposited within the PEI film
yields higher NO fluxes, indicating the ability of our approach to finetune NO fluxes to meet requirements of optimum release for varying
applications.

4.3.4 PLATELET ADHESION STUDIES
To evaluate the thromboresistivity of the NOS based polymeric
coatings in vitro, ITO slides, glass substrates that offer the advantage of
being conductive, were coated with the NOS containing polymer (Figure
4.8B), as well as BSA containing polymer (Figure 4.8A) (negative
control). Those slides were incubated with platelet rich plasma for 1 hour
at 37°C, and then rinsed with PBS buffer. Phase contrast microscopy
images of NO releasing NOS based polymers (Figure 4.8D) consistently
showed almost no platelet adhesion at the surface when compared with a
negative control (Figure 4.8C), indicating an overall enhancement of the
thromboresistive properties of those coatings.
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A

B

C

D

Figure 4.8: Phase contrast microscopy images pre-incubation of A)
PEI/BSA film and B) PEI/NOS film, and post incubation with platelet
rich plasma C) PEI/BSA film and D) PEI/NOS.
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4.3.5 LACTATE DEHYDROGENASE ASSAY

LDH assay is useful in quantifying cell and platelet adhesion at the
surface of the PEI/NOS coatings. LDH is an enzyme found in cells at
levels proportional to its size [45], and is released following cell
breakdown. In vitro determination of the degree of platelet adhesion to
surfaces using LDH assay has been reported [45-47].
Figure 4.9 reveals the corresponding LDH level results of uncoated
surface (bare) 0.16±0.04 (N=7), 5 layer coating (5 layers of NOS)
0.11±0.01 (N=7), and 10 layer coating (10 layers of NOS) 0.06±0.01
(N=7).
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Figure 4.9: LDH assay of platelet adhesion on the surface of the
PEI/NOS coatings.
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In figure 4.10, the mean LDH activity at the bare surface was considered
to correspond to 100% adhesion, and a decreased amount of adhered
platelets was seen with the 5 layer coatings (69.8%) and with the 10 layer
coatings (39.3%).
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Figure 4.10: Percentage platelet adhesion on the surface of the PEI/NOS
coatings.
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As expected, the results presented reveals that the increasing
number of NOS layers within the PEI/NOS coating corresponding to
higher NO fluxes, reduced platelet adhesion in vitro up to 60.7%. The
inhibition of platelet adhesion is a critical step in inhibiting thrombus
formation at the surface of implantable medical devices. The enhanced
thromboresistivity displayed by these coatings provide the basis of future
endeavors in developing more biocompatible coatings for surface
modifications of implantable medical devices.

4.4 CONCLUSIONS
Thrombus formation at the surface of implantable medical
devices is the major cause of vascular access dysfunction requiring
secondary vascular procedures. NO releasing bio-polymers are being
sought as an effective anti-thrombotic coatings in an attempt to enhance
thromboresistivity of those devices. The approaches utilizing NO-donors
incorporated into polymeric matrices suffer from being a finite NO
reservoir, and thus they are limited in their ability to sustain NO fluxes
over a prolonged period of time. We presented a logical alternative that
explores approaches aiming at developing materials with the ability to
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sustain NO release for longer durations and at levels comparable to
stimulated human endothelial cells (0.5-4x10-10 molcm-2min-1) [16].
NOS based polyethyleneimine coatings were successfully
developed with the layer-by-layer methodology. NO was successfully
generated from these coatings at levels comparable to stimulated human
endothelial cells. NO release from these NOS-based coatings
successfully decreased platelet adhesion at the surface by 60%, which
potentially might lead to improved thromboresistivity of implantable
devices when coated with those materials.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS

5.1 CONCLUSIONS

During the past century, the use of implantable medical devices
and other blood contacting biomedical devices have evolved from a mere
dream to a widely adopted medical practice, including the use of stents,
vascular grafts, sensors, pacemakers, heart valves, hemodialyzers,
extracorporeal circuits, and membrane oxygenators [1, 2]. However, one
of the major problems associated with these devices, is that the
introduction of such devices leads to injury of the blood vessel walls.
Clot formation or thrombosis also results at the injured site, causing
stenosis or occlusion of the blood vessel. Moreover, if the medical device
is left within the patient for an extended period of time, thrombus
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ultimately forms on the device itself, again causing stenosis or occlusion.
The driving force behind these issues is the lack of hemocompatibility of
the

polymeric

materials

used

to

prepare

such

devices.

The

biocompatibility of an implantable medical device is defined as the
ability of the device to perform its intended function, with the desired
incorporation within the host, without eliciting any undesirable local or
systemic effects in that host [3]. There exists a need for modification of
medical

devices,

with

materials

capable

of

enhancing

the

biocompatibility of these devices from the first instance of blood and
tissue contact to days or weeks following its first use. The best-known
example of a completely non-thrombogenic surface is the vascular
endothelium that lines the inner walls of all blood vessels. The biological
responses underlining the biocompatibility of this lining are mediated by
a number of active molecules that are either expressed at the surface such
as heparan sulfate, and thrombomodulin [4], or are continuously being
secreted such as prostacyclin, plasminogen, antithrombin III and Nitric
Oxide (NO) [5].
NO releasing bio-polymers are being sought as effective antithrombotic coatings in an attempt to enhance thromboresistivity of those
devices. The approaches utilizing NO-donors incorporated into polymeric
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matrices suffer from being a finite NO reservoir, and thus they are
limited in their ability to sustain NO fluxes over a prolonged period of
time. The alternative is then to explore approaches that would lead to
materials with the ability to sustain NO generation for longer durations
and at levels comparable to stimulated human endothelial cells (0.5 4x10-10 molcm-2min-1) [6]. NOS based polyethyleneimine coatings were
successfully developed with the layer-by-layer methodology. NO was
successfully generated from these coatings at levels comparable to
stimulated human endothelial cells. NO release from these coatings
successfully decreased platelet adhesion at the surface by 60%, which
leads to improved thromboresistivity of implantable devices when coated
with those materials.

5.2 FUTURE DIRECTIONS

Various efforts have been made to prepare more blood
compatible surfaces that include NO-release (anti-platelet activity),
heparin bound (anticoagulant activity) [7], or thrombomodulinimmobilized polymeric coatings [8]. The potency of such materials in
preventing clot formation may be limited to the fact that these materials

147

partially address the thromboresistivity issues. These materials possess
partial thromboreisistivity (either anti-platelet or anticoagulant activity).
The alternative could be the development of surfaces that integrates both
anti-platelet and anticoagulant agents that will act synergistically to
achieve higher thromboresistivity levels. The integration of a
combination of the agents that possess anti-platelet and anticoagulant
activity into a polymeric matrix in such a manner that they are either
released or are immobilized on the surface should result in a ‘truly’
biomimetic coating that closely resembles the endothelial cell lining of
the inner blood vessel wall.
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Figure 5.1: A schematic illustration of liposome surface glycofunctionalization through the Staudinger ligation. Adapted from [9]
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Polymeric materials that combine NO release with surfacebound heparin have been developed in an initial effort to towards the
fabrication of polymeric coating that truly mimic the endothelial cell
functionality [10]. Thrombomodulin, a 74 kDa transmembrane protein
acts as a modulator of thrombin activity in vivo [4]. Once thrombin binds
to thrombomodulin on the endothelial cell surface, thrombin’s fibrinogen
cleaving activity is inhibited. In addition, the protein C anti-coagulation
pathway is activated by this binding leading to the change of thrombin
from a procoagulant state to an anti-coagulant state [11]. Multifunctional
bilayer polymeric coatings have been recently described with both
controlled NO release and surface bound active thrombomodulin or
combined thrombomodulin and heparin that mimic the highly
thromboresistant endothelium layers [12]. In addition, liposomes have
been presented as candidates to prepare biomimetic coatings intended to
enhance the biocompatibility of implantable medical devices [13].
Pancreatic Islets with recombinant azido-thrombomdulin were prepared
by

the

chemoselective

conjugation

of

an

azido-functionalized

thrombomodulin [14], to pancreatic islets by Staudinger ligation to a
surface-bound bifunctional poly(ethylene glycol) linker (Figure 5.1). The
presence of thrombomodulin on the surface was associated with a
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significant increase in the production of activated protein C with a
reduction in the islet-mediated thrombogenicity [9].
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Figure 5.2: Schematic illustration of Liposomes that are capable of
releasing Nitric Oxide with surface bound recombinant truncated
thrombomodulin and heparin

152

Liposomes that are capable of releasing Nitric Oxide with surface bound
thrombomodulin and heparin (Figure 5.2) appear to be a potential target
to prepare biomimetic coatings that can be applied to surfaces of
implantable medical devices to enhance their thromboresistivity and
biocompatibility.
We demonstrate in this chapter the preliminary work involving the
sub-cloning of a methionine-deficient thrombomodulin construct,
followed by the subsequent expression and purification of the
recombinant

truncated

thrombomodulin

containing

an

azido-

functionalized methionine analog as a C-terminal linker for site-specific
functionalization using the Staudinger ligation [9].

5.2.1 Sub-cloning of Recombinant Truncated Thrombomodulin

A

DNA

fragment

encoding

for

the

truncated

human

thrombomodulin, containing N-terminal BAMHI restriction site and a Cterminal linker Gly Gly Met, was obtained by Polymerase Chain
Reaction, by using the wild type thrombomodulin plasmid DNA as a
template

and

primers

GGATCCGTACCCTAACTACGACCTGGTG-3',
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Forward:
and

Reverse:

5'5'-

TTACATTCCACCTATGAGCAAGCCCGAATG-3'. The TOPO TA
vector kit was used for the sub-cloning of the PCR products and the
subsequent analysis of positive clones by restriction digestion using the
BAMH I restriction enzyme. Site-directed mutagenesis was performed
using primers Forward: 5’-CAGGTGCCAGCTGTTTTGCAACC-3’ and
Reverse: 5’-GGTTGCAAAACAGCTGGCACCTG-3’ to generate a
leucine (Leu) substitution for methionine-407 (M407L). The final
construct (recombinant truncated thrombomodulin) was then inserted
using the BAMHI site of the expression plasmid pET-39b(+) (Figure
5.3). The expression plasmid pET-39b(+) containing the recombinant
thrombomodulin

insert

was

sequence-verified

and

subsequently

transformed into the E.coli methionine auxotroph B834(DE3).
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Figure 5.3: DNA gel electrophoresis depicting the size of the insert
ligated with the pET-39b (+) plasmid.
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5.2.2 Protein Expression and Purification

M9 minimal medium (500 mL), supplemented with 1 mM MgSO4,
0.4 wt % glucose, 1mg/L thiamine chloride, 0.1 mM CaCl2, kanamycin
(30mg/L), and all proteinogenic amino acids (40 mg/L), was inoculated
with 20 mL of an overnight culture of the transformed cells. When the
turbidity of the culture reached an OD600 of 0.8, protein expression was
induced by addition of isopropyl-â-D-thiogalactopyranoside (IPTG) to a
final concentration of 0.5 mM. After 5 min, the medium was exchanged
to remove methionine, cells were sedimented (4000g for 20 min), and the
cell pellet was washed twice with 200 mL of 1X M9 salts. Cells were
resuspended in 500 mL of the M9 minimal medium described above,
without methionine but supplemented with 100 mg/L of azidofunctionalized methionine analogue. Cultures were grown for 4.5 h at 37
°C. The cells were first harvested by centrifugation at 4 °C at 10000g for
30 min and resuspended in 25mL of M9 buffer (1X M9 salts, 10%
glycerol, 1 mg/mL lysozyme, and 10 µg/mL PMSF), and then the cells
were lysed by sonication. The cell lysate was clarified by centrifugation
at 10000g for 20 min. The supernatant was filtered through a 0.45µm
syringe filters and then loaded onto a His-tag column. The presence of
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thrombomodulin as an end product was confirmed using SDS-PAGE and
quantified using S TAG rapid assay. Lane 5, features a band that
corresponds to 36kDa in size confirming the presence of the truncated
recombinant thrombomodulin. The average yield is 9.24mg of protein per
liter of cell culture.
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36 kDa

Figure 5.4: SDS PAGE of purified methionine deficient truncated
recombinant thrombomodulin

158

5.3 REFERENCES

1. Peppas, N.A. and R. Langer, New challenges in biomaterials. Science,
1994. 263(5154): p. 1715-20.
2. Ratner, B.D., Blood compatibility--a perspective. J Biomater Sci
Polym Ed, 2000. 11(11): p. 1107-19.
3. Williams, D., Year-end perspectives: the introduction of new
technologies. Med Device Technol, 2003. 14(10): p. 10-2.
4. Wen, D.Z., et al., Human thrombomodulin: complete cDNA sequence
and chromosome localization of the gene. Biochemistry, 1987.
26(14): p. 4350-7.
5. Coleman, R.W., Mechanism of thrombus formation and dissolution.
Cardiovascular Pathology, 1993. 2: p. 23S-31S.
6. Vaughn, M.W., L. Kuo, and J.C. Liao, Estimation of nitric oxide
production and reaction rates in tissue by use of a mathematical
model. Am J Physiol, 1998. 274(6 Pt 2): p. H2163-76.
7. Wissink, M.J., et al., Immobilization of heparin to EDC/NHScrosslinked collagen. Characterization and in vitro evaluation.
Biomaterials, 2001. 22(2): p. 151-63.

159

8. Sperling, C., et al., Covalently immobilized thrombomodulin inhibits
coagulation and complement activation of artificial surfaces in vitro.
Biomaterials, 2004. 25(21): p. 5101-13.
9. Stabler, C.L., et al., Surface re-engineering of pancreatic islets with
recombinant azido-thrombomodulin. Bioconjug Chem, 2007. 18(6): p.
1713-5.
10.Zhou, Z. and M.E. Meyerhoff, Preparation and characterization of
polymeric coatings with combined nitric oxide release and
immobilized active heparin. Biomaterials, 2005. 26: p. 6506-6517.
11.Sadler, J.E., Thrombomodulin structure and function. Thromb
Haemost, 1997. 78(1): p. 392-5.
12.Wu, B., et al., Polymeric coatings that mimic the endothelium:
combining

nitric

oxide

release

with

surface-bound

active

thrombomodulin and heparin. Biomaterials, 2007. 28(28): p. 4047-55.
13.Valenzuela, S.M., Liposome Techniques for Synthesis of Biomimetic
Lipid Membranes, in Nanobiotechnology of Biomimetic Membranes,
D.K. Martin, Editor. 2007, Springer US. p. 75-87.
14.Cazalis, C.S., et al., C-terminal site-specific PEGylation of a
truncated thrombomodulin mutant with retention of full bioactivity.
Bioconjug Chem, 2004. 15(5): p. 1005-9.

160

